 PARISBUSINESS WIRERegulatory News: Ipsen Euronext: IPN; ADR: IPSEY today presented positive results from the pivotal Phase III NAPOLI 3 trial evaluating an investigational regimen of Onivyde irinotecan liposome injection, a long-circulating, liposomal topoisomerase inhibitor, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma mPDAC. In a late-breaking abstracts session presentation LBA661 at the 2023 American ... Ipsen Presents Phase III NAPOLI 3 Tria... 